The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis
Abstract
Purpose: The present review aims to emphasize that malignant gliomas are characterized by the diffuse invasion of distant brain tissue by a myriad of single migrating cells that exhibit decreased levels of apoptosis (programmed cell death type I), thus a resistance to cytotoxic insult. Methods: The present review surveys the molecular mechanisms of migration in malignant gliomas and potential issues arising from treatments, in addition to relationships between glioma cell migration and resistance to apoptosis in terms of the molecular signaling pathways. Results: Clinical and experimental data demonstrate that glioma cell migration is a complex combination of multiple molecular processes, including the alteration of tumor cell adhesion to a modified extracellular matrix, the secretion of proteases by the cells, and modifications to the actin cytoskeleton. Intracellular signaling pathways involved in the acquisition of resistance to apoptosis by migrating glioma cells concern PI3K, Akt, mTOR, NF-κB, and autophagy (programmed cell death type II). Conclusion: A number of signaling pathways can be constitutively activated in migrating glioma cells, thus rendering these cells resistant to cytotoxic insults. However, these pathways are not all constitutively activated at the same time in any one glioma. Particular inhibitors should therefore only be chosen if the target is present in the tumor tissue, but this is only possible if individual patients are submitted to the molecular profiling of their tumors before undergoing any treatment to combat their migratory glioma cells. Specific antimigratory compounds should be added to conventional radio- and/or chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Cell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Pierschbacher, M. D., & Ruoslahti, E. (1984) · Nature · doi:10.1038/309030a0 · Cited by 3,658
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Pathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness
Palecek, S. P., Loftus, J. C., Ginsberg, M. H., Lauffenburger, D. A., & Horwitz, A. F. (1997) · Nature · doi:10.1038/385537a0 · Cited by 1,427
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Ulrich, T. A., de Juan Pardo, E. M., & Kumar, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4859 · Cited by 901
Galectin-1: a small protein with major functions
Camby, I., Le Mercier, M., Lefranc, F., & Kiss, R. (2006) · Glycobiology · doi:10.1093/glycob/cwl025 · Cited by 893
Self-citationDiffuse glioma growth: a guerilla war
Claes, A., Idema, A. J., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0293-7 · Cited by 636
Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research
Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 381
Shifting the optimal stiffness for cell migration
Bangasser, B. L., Shamsan, G. A., Chan, C. E., Opoku, K. N., Tüzel, E., Schlichtmann, B. W., Kasim, J. A., Fuller, B. J., McCullough, B. R., Rosenfeld, S. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15313 · Cited by 328
Cardiotonic steroids on the road to anti-cancer therapy
Mijatovic, T., Van Quaquebeke, E., Delest, B., Debeir, O., Darro, F., & Kiss, R. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.06.002 · Cited by 317
Self-citationKim, E. H., Sohn, S., Kwon, H. J., Kim, S. U., Kim, M.-J., Lee, S.-J., & Choi, K. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4217 · Cited by 251
Lefranc, F., Facchini, V., & Kiss, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1395 · Cited by 237
“Given that autophagy is decreased or suppressed during the early stages of tumor progression and cancer cells carry mutations that inactivate apoptotic pathways [3, 12, 17 ], therapeutically increasing autophagy couldrepresentanalternativemeanstodestroycancercells.”
BackgroundSelf-citationActive Ras Triggers Death in Glioblastoma Cells through Hyperstimulation of Macropinocytosis
Overmeyer, J. H., Kaul, A., Johnson, E. E., & Maltese, W. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2036 · Cited by 229
Bronisz, A., Wang, Y., Nowicki, M. O., Peruzzi, P., Ansari, K. I., Ogawa, D., Balaj, L., De Rienzo, G., Mineo, M., Nakano, I., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2650 · Cited by 222
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201
5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma
Coupienne, I., Fettweis, G., Rubio, N., Agostinis, P., & Piette, J. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05213f · Cited by 91
Li, J., Gong, L.-Y., Song, L.-B., Jiang, L.-L., Liu, L.-P., Wu, J., Yuan, J., Cai, J.-C., He, M., Wang, L., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090502 · Cited by 84
Coupienne, I., Bontems, S., Dewaele, M., Rubio, N., Habraken, Y., Fulda, S., Agostinis, P., & Piette, J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.015 · Cited by 83
Reed, J. E., Dunn, J. R., Du Plessis, D. G., Shaw, E. J., Reeves, P., Gee, A. L., Warnke, P. C., Sellar, G. C., Moss, D. J., & Walker, C. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00786.x · Cited by 61
Metadata
- Authors
- Lefranc, F., Brotchi, J., & Kiss, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-01
- Volume
- 23
- Issue
- 10
- Pages
- 2411-2422
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1997773537
- Cited by
- 526
- References
- 116
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.